Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry.
paper
Cited
Public
Unavailable
- Authors
- So, Hon-Cheong; Chau, Carlos Kwan-Long; Chiu, Wan-To; Ho, Kin-Sang; Lo, Cho-Pong; Yim, Stephanie Ho-Yue; Sham, Pak-Chung
- Year
- 2017
- Journal
- Nature neuroscience
- PMID
- 28805813
- DOI
- 10.1038/nn.4618
Knowledge of psychiatric disease genetics has advanced rapidly during the past decade with the advent of genome-wide association studies (GWAS). However, less progress has been made in harnessing these data to reveal new therapies. Here we propose a framework for drug repositioning by comparing transcriptomes imputed from GWAS data with drug-induced gene expression profiles from the Connectivity Map database and apply this approach to seven psychiatric disorders. We found a number of repositioning candidates, many supported by preclinical or clinical evidence. Repositioning candidates for a number of disorders were also significantly enriched for known psychiatric medications or therapies considered in clinical trials. For example, candidates for schizophrenia were enriched for antipsychotics, while those for bipolar disorder were enriched for both antipsychotics and antidepressants. These findings provide support for the usefulness of GWAS data in guiding drug discovery.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A genetics-guided integrative framework for drug repurposing: identifying antihypertensive drugs for type 2 diabetes. | Zhong X et al. | β | 2026 | β |
| Multi-omics approaches to major psychiatric disorders. | Oraki Kohshour M et al. | β | 2026 | β |
| A computational genetic- and transcriptomics-based study nominates drug repurposing candidates for the treatment of chronic pain. | Cote AC et al. | β | 2025 | β |
| Application of GWAS summary data and drug-induced gene expression profiles of neural progenitor cells in psychiatric drug prioritization analysis. | Li X et al. | β | 2025 | β |
| Dysregulated Pathways During Pregnancy Predict Drug Candidates in Neurodevelopmental Disorders. | Yin H et al. | β | 2025 | β |
| Genetic Studies Through the Lens of Gene Networks. | Subirana-GranΓ©s M et al. | β | 2025 | β |
| Identifying compounds to treat opiate use disorder by leveraging multi-omic data integration and multiple drug repurposing databases. | Stratford JK et al. | β | 2025 | β |
| Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders. | Arnatkeviciute A et al. | β | 2025 | β |
| Network-based drug repurposing for psychiatric disorders using single-cell genomics. | Gupta C et al. | β | 2025 | β |
| Pharmaco-Multiomics: A New Frontier in Precision Psychiatry. | Dhieb D et al. | β | 2025 | β |
| A versatile attention-based neural network for chemical perturbation analysis and its potential to aid surgical treatment: an experimental study. | Fan Z et al. | β | 2024 | β |
| From genetic associations to genes: methods, applications, and challenges. | Qi T et al. | β | 2024 | β |
| Harnessing transcriptomic signals for amyotrophic lateral sclerosis to identify novel drugs and enhance risk prediction. | Pain O et al. | β | 2024 | β |
| Mapping drug biology to disease genetics to discover drug impacts on the human phenome. | Habib M et al. | β | 2024 | β |
| Multi-ancestry meta-analysis of tobacco use disorder identifies 461 potential risk genes and reveals associations with multiple health outcomes. | Toikumo S et al. | β | 2024 | β |
| Novel insight into the etiology of ischemic stroke gained by integrative multiome-wide association study. | Jung J et al. | β | 2024 | β |
| Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective. | Etkin A et al. | β | 2024 | β |
| PharmGWAS: a GWAS-based knowledgebase for drug repurposing. | Kang H et al. | β | 2024 | β |
| The effects of methylphenidate and atomoxetine on Drosophila brain at single-cell resolution and potential drug repurposing for ADHD treatment. | Qu S et al. | β | 2024 | β |
| Transcriptome-Wide Association Studies (TWAS): Methodologies, Applications, and Challenges. | Evans P et al. | β | 2024 | β |
| Transcriptomic imputation of genetic risk variants uncovers novel whole-blood biomarkers of Parkinson's disease. | Chew G et al. | β | 2024 | β |
| 15 years of GWAS discovery: Realizing the promise. | Abdellaoui A et al. | β | 2023 | β |
| Computational drug repurposing by exploiting large-scale gene expression data: Strategy, methods and applications. | He H et al. | β | 2023 | β |
| Examining the shared etiology of psychopathology with genome-wide association studies. | Mallard TT et al. | β | 2023 | β |
| Mapping drug biology to disease genetics to discover drug impacts on the human phenome | Habib M et al. | β | 2023 | β |
| Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals. | Zhou H et al. | β | 2023 | β |
| New "drugs and targets" in the GWAS era of bipolar disorder. | Qi HX et al. | β | 2023 | β |
| Papaverine: A Miraculous Alkaloid from Opium and Its Multimedicinal Application. | Ashrafi S et al. | β | 2023 | β |
| Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms. | Pividori M et al. | β | 2023 | β |
| Transcriptome-Wide Structural Equation Modeling of 13 Major Psychiatric Disorders for Cross-Disorder Risk and Drug Repurposing. | Grotzinger AD et al. | β | 2023 | β |
| A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. | Namba S et al. | β | 2022 | β |
| A systems medicine strategy to predict the efficacy of drugs for monogenic epilepsies. | Taweel B et al. | β | 2022 | β |
| A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility. | Voloudakis G et al. | β | 2022 | β |
| CeDR Atlas: a knowledgebase of cellular drug response. | Wang YY et al. | β | 2022 | β |
| Controlling astrocyte-mediated synaptic pruning signals for schizophrenia drug repurposing with deep graph networks. | Gravina A et al. | β | 2022 | β |
| From pharmacogenetics to pharmaco-omics: Milestones and future directions. | Auwerx C et al. | β | 2022 | β |
| Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension. | Wu P et al. | β | 2022 | β |
| Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction. | Guan F et al. | β | 2022 | β |
| Overview of CAPICE-Childhood and Adolescence Psychopathology: unravelling the complex etiology by a large Interdisciplinary Collaboration in Europe-an EU Marie SkΕodowska-Curie International Training Network. | Rajula HSR et al. | β | 2022 | β |
| Substance use and common contributors to morbidity: A genetics perspective. | Sanchez-Roige S et al. | β | 2022 | β |
| Transcriptomic effects of propranolol and primidone converge on molecular pathways relevant to essential tremor. | Castonguay CE et al. | β | 2022 | β |
| Vorinostat Corrects Cognitive and Non-Cognitive Symptoms in a Mouse Model of Fragile X Syndrome. | Ding Q et al. | β | 2022 | β |
| An interview with Dr Chiara Fabbri: pharmacogenomics and drug repurposing for treatment-resistant depression. | Fabbri C | β | 2021 | β |
| Causal Inference Methods to Integrate Omics and Complex Traits. | Porcu E et al. | β | 2021 | β |
| Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions. | McCracken JT et al. | β | 2021 | β |
| Drug repositioning based on network-specific core genes identifies potential drugs for the treatment of autism spectrum disorder in children. | Gao H et al. | β | 2021 | β |
| Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. | Fabbri C et al. | β | 2021 | β |
| Drug repurposing strategies of relevance for Parkinson's disease. | Fletcher EJR et al. | β | 2021 | β |
| Drug Repurposing to Treat Glucocorticoid Resistance in Asthma. | Wang AL et al. | β | 2021 | β |
| From serendipity to rational drug design in brain disorders: in silico, inΒ vitro, and inΒ vivo approaches. | Oh H et al. | β | 2021 | β |
| Genetic architecture of four smoking behaviors using partitioned SNP heritability. | Evans LM et al. | β | 2021 | β |
| Genetic contributions to anxiety disorders: where we are and where we are heading. | Ask H et al. | β | 2021 | β |
| Genetics of substance use disorders: a review. | Deak JD et al. | β | 2021 | β |
| Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. | Lam M et al. | β | 2021 | β |
| Integrative Network-Based Analysis Reveals Gene Networks and Novel Drug Repositioning Candidates for Alzheimer Disease. | Gerring ZF et al. | β | 2021 | β |
| Novel characterization of the multivariate genetic architecture of internalizing psychopathology and alcohol use. | Colbert SMC et al. | β | 2021 | β |
| Signature-based approaches for informed drug repurposing: targeting CNS disorders. | Shukla R et al. | β | 2021 | β |
| Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example. | Imami AS et al. | β | 2021 | β |
| Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. | Fabbri C et al. | β | 2021 | β |
| Translational genomics and beyond in bipolar disorder. | Zhang C et al. | β | 2021 | β |
| Using common genetic variants to find drugs for common epilepsies. | Mirza N et al. | β | 2021 | β |
| Drug databases and their contributions to drug repurposing. | Masoudi-Sobhanzadeh Y et al. | β | 2020 | β |
| Fine-mapping and QTL tissue-sharing information improves the reliability of causal gene identification. | Barbeira AN et al. | β | 2020 | β |
| Genetic Risk of Autism Spectrum Disorder in a Pakistani Population. | Khalid M et al. | β | 2020 | β |
| Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment. | Fabbri C et al. | β | 2020 | β |
| Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. | Fang J et al. | β | 2020 | β |
| Matrix Factorization-based Technique for Drug Repurposing Predictions. | Ceddia G et al. | β | 2020 | β |
| PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures. | Emon MA et al. | β | 2020 | β |
| Revealing the structure of pharmacobehavioral space through motion sequencing. | Wiltschko AB et al. | β | 2020 | β |
| Screening novel drug candidates for Alzheimer's disease by an integrated network and transcriptome analysis. | Peng Y et al. | β | 2020 | β |
| Systemic neuro-dysregulation in depression: Evidence from genome-wide association. | Tubbs JD et al. | β | 2020 | β |
| Transcriptome signature analysis repurposes trifluoperazine for the treatment of fragile X syndrome in mouse model. | Ding Q et al. | β | 2020 | β |
| Transcriptome-wide association analysis offers novel opportunities for clinical translation of genetic discoveries on mental disorders. | Derks EM et al. | β | 2020 | β |
| Translating insights from neuropsychiatric genetics and genomics for precision psychiatry. | Rees E et al. | β | 2020 | β |
| Turning genome-wide association study findings into opportunities for drug repositioning. | Lau A et al. | β | 2020 | β |
| An Integrated System Biology Approach Yields Drug Repositioning Candidates for the Treatment of Heart Failure. | Yang G et al. | β | 2019 | β |
| Bioinformatic and biological avenues for understanding alcohol use disorder. | Grantham EK et al. | β | 2019 | β |
| Decoding the transcriptional programs activated by psychotropic drugs in the brain. | Zygmunt M et al. | β | 2019 | β |
| Drug repurposing for Alzheimer's disease based on transcriptional profiling of human iPSC-derived cortical neurons. | Williams G et al. | β | 2019 | β |
| Drug Repurposing Prediction for Immune-Mediated Cutaneous Diseases using a Word-Embedding-Based Machine Learning Approach. | Patrick MT et al. | β | 2019 | β |
| Efficient Prediction of Vitamin B Deficiencies via Machine-Learning Using Routine Blood Test Results in Patients With Intense Psychiatric Episode. | Tamune H et al. | β | 2019 | β |
| Functionally oriented analysis of cardiometabolic traits in a trans-ethnic sample. | Petty LE et al. | β | 2019 | β |
| Integrating Clinical Data and Imputed Transcriptome from GWAS to Uncover Complex Disease Subtypes: Applications in Psychiatry and Cardiology. | Yin L et al. | β | 2019 | β |
| Integrative transcriptome imputation reveals tissue-specific and shared biological mechanisms mediating susceptibility to complex traits. | Zhang W et al. | β | 2019 | β |
| In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned. | Lipponen A et al. | β | 2019 | β |
| Pharmacogenetics and Depression: A Critical Perspective. | Corponi F et al. | β | 2019 | β |
| Recent advances in understanding of attention deficit hyperactivity disorder (ADHD): how genetics are shaping our conceptualization of this disorder. | Zayats T et al. | β | 2019 | β |
| Translating GWAS findings into therapies for depression and anxiety disorders: gene-set analyses reveal enrichment of psychiatric drug classes and implications for drug repositioning. | So HC et al. | β | 2019 | β |
| Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates. | Vita A et al. | β | 2019 | β |
| Using Drug Expression Profiles and Machine Learning Approach for Drug Repurposing. | Zhao K et al. | β | 2019 | β |
| Using genetic drug-target networks to develop new drug hypotheses for major depressive disorder. | Gaspar HA et al. | β | 2019 | β |
| Discoveries on the Genetics of ADHD in the 21st Century: New Findings and Their Implications. | Thapar A | β | 2018 | β |
| From gene networks to drugs: systems pharmacology approaches for AUD. | Ferguson LB et al. | β | 2018 | β |
| Genome-Wide Expression Profiles Drive Discovery of Novel Compounds that Reduce Binge Drinking in Mice. | Ferguson LB et al. | β | 2018 | β |
| Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. | International League Against Epilepsy Consortium on Complex Epilepsies | β | 2018 | β |
| Network-based drug repositioning: A novel strategy for discovering potential antidepressants and their mode of action. | Zhang TT et al. | β | 2018 | β |
| Post-GWAS in Psychiatric Genetics: A Developmental Perspective on the "Other" Next Steps. | Dick DM et al. | β | 2018 | β |
| Re-thinking Alzheimer's disease therapeutic targets using gene-based tests. | Kwok MK et al. | β | 2018 | β |
| The genetics of human personality. | Sanchez-Roige S et al. | β | 2018 | β |
| The vagal ganglia transcriptome identifies candidate therapeutics for airway hyperreactivity. | Reznikov LR et al. | β | 2018 | β |
| Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease. | Shu L et al. | β | 2018 | β |